Averill Master Fund, Ltd.
Director, 10% Owner · Benitec Biopharma Inc.
Every open-market stock purchase Averill Master Fund, Ltd. has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- BNTC+26.8% vs price paidBenitec Biopharma Inc.
2 purchases totalling $369.9K at an average of $10.05 per share; the stock last traded at $12.75. See all insider buying in BNTC →
Avg price paid$10.05Latest price$12.75Market cap$436.0M
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
Follow new qualifying clusters involving Averill Master Fund, Ltd. or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from Averill Master Fund, Ltd.'s Form 4 filings on SEC EDGAR (CIK 1939329) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.